Vertex Pharmaceuticals Publishes Presentation on Kidney Disease Research

• Vertex Pharmaceuticals published its “Vertex 2026 Final ASN Presentation,” outlining kidney drug trial results and development milestones.
• Povetacicept reduced proteinuria by 52% at Week 36 in the Phase 3 RAINIER interim analysis; the placebo-adjusted reduction was 49.8%.
• Serious adverse events occurred in 3% of povetacicept recipients versus 4.3% with placebo.
• A November 30 PDUFA target date is set for povetacicept in IgA nephropathy.
• Inaxaplin’s pivotal AMPLITUDE trial is fully enrolled, with interim analysis data expected in early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertex Pharmaceuticals Incorporated published the original content used to generate this news brief on October 24, 2026, and is solely responsible for the information contained therein.